Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
How to Trip Rapid Review
Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)
Step 2: press
Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.
Collaborator: Progenics Pharmaceuticals, Inc. Information provided by (Responsible Party): Edward Schaeffer, Northwestern University Study Details Study Description Go to Brief Summary: The purpose of this study is to gain understanding of how PET-MR (positron emission tomography-magnetic resonance imaging) using the substance 18F-DCFPyL (PyL) may help in diagnosing prostatecancer and in determining the stage of prostatecancer before surgery. Condition or disease Intervention/treatment Phase Prostate (...) PET/MRI for the Staging of Newly Diagnosed ProstateCancer PET/MRI for the Staging of Newly Diagnosed ProstateCancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. PET/MRI for the Staging of Newly
Ultra-small superparamagnetic iron oxide contrast agents for lymph node staging of high-risk prostatecancer Ultrasmall superparamagnetic particles of iron oxide (USPIOs) imaged with magnetic resonance imaging (MRI) have been proposed as an experimental method for visualizing lymph node (LN) metastases. The method does not require ionizing radiation, yet can detect small nodes that are involved with metastases. USPIOs are naturally taken up by macrophages that deposit in the normal LN creating (...) a low signal region in normal areas; areas within the node that do not show this loss of signal are likely involved by tumor although there can be other causes (fibrosis or inflammation). However, the lack of approved USPIOs that are clinically available hinders adoption and larger studies. The proposed indications for USPIO MRI, including specific compounds and imaging methods are discussed.
EphA2 Is a Potential Player of Malignant Cellular Behavior in Non-Metastatic Renal Cell Carcinoma Cells but Not in Metastatic Renal Cell Carcinoma Cells To investigate the role of EphA2 in malignant cellular behavior in renal cell carcinoma (RCC) cells and whether FAK/RhoA signaling can act as downstream effectors of EphA2 on RCC cells.Expression of EphA2 protein in non-metastatic RCC (Caki-2 and A498), metastatic RCC cells (Caki-1 and ACHN), HEK-293 cells and prostatecancer cells (PC-3 and DU (...) plays a critical role in the malignant cellular behavior of RCC and appears to be functional particularly in the early stage of malignant progression of non-metastatic RCC.
and identifying optimal treatment, while considering such factors as diseasestage, risk, volume, age, and performance status. The purpose of this American Society of Clinical Oncology (ASCO) guideline is to endorse the American Urological Association (AUA), American Society for Radiation Oncology (ASTRO), and Society of Urologic Oncology (SUO) guideline on Clinically Localized ProstateCancer by Sanda et al, , which was published online in 2017 (available at ) and in print in 2018. This ASCO endorsement (...) POPULATION Section: The Clinically Localized ProstateCancer guideline made recommendations according to shared decision making, cancer severity/risk group (very low– and low-risk disease, intermediate-risk disease, high-risk disease), recommended treatment approaches (active surveillance, prostatectomy, radiotherapy, cryosurgery, high intensity focal ultrasound/focal therapy), and outcome expectations and management (treatment-related adverse events and health-related quality of life, post-treatment
Early Detection of ProstateCancerProstateCancer: Early Detection Guideline - American Urological Association advertisement Toggle navigation About Us About the AUA Membership AUA Governance Industry Relations Education AUAUniversity Education Products & Resources Normal Histology and Important Histo-anatomic Structures Urinary Bladder Prostate Kidney Renovascular Diseases Andrenal Gland Testis Paratesticular Tumors Penis Retroperitoneum Cytology Online Learning For Medical Students Exams/LLL (...) and Quality of Care Accreditations and Reporting Patient Education Early Detection of ProstateCancer (2018) Published 2013; Reviewed and Validity Confirmed 2018 The clinical guideline on Early Detection of ProstateCancer discusses the detection of disease at an early, pre-symptomatic stage through the use of screening tools, such as PSA. Early detection allows for more conservative management, if needed, via means such as active surveillance and watchful waiting. [pdf] Panel Members H. Ballentine Carter
Hypofractionated Radiation Therapy for Localized ProstateCancerProstateCancer: Hypofractionated Radiotherapy Guideline - American Urological Association advertisement Toggle navigation About Us About the AUA Membership AUA Governance Industry Relations Education AUAUniversity Education Products & Resources Normal Histology and Important Histo-anatomic Structures Urinary Bladder Prostate Kidney Renovascular Diseases Andrenal Gland Testis Paratesticular Tumors Penis Retroperitoneum Cytology (...) is considered low compared to most other neoplasms, with several estimates derived from large populations in the range of 100 to 200 cGy. 5-7 Unlike other solid tumors with higher alpha-beta ratios, the alpha-beta ratio of the adjacent dose-limiting normal structure, namely the rectum, has been estimated to be greater than that of prostatecancer itself. 8,9 An implication of this relationship is that hypofractionation - daily delivery of EBRT with fraction sizes >200 cGy - may further improve
Castration-Resistant ProstateCancerProstateCancer: Castration Resistant Guideline - American Urological Association advertisement Toggle navigation About Us About the AUA Membership AUA Governance Industry Relations Education AUAUniversity Education Products & Resources Normal Histology and Important Histo-anatomic Structures Urinary Bladder Prostate Kidney Renovascular Diseases Andrenal Gland Testis Paratesticular Tumors Penis Retroperitoneum Cytology Online Learning For Medical Students (...) and dangerous drug interactions. This document was amended in April 2014 and March 2015 to reflect literature that was released since the original publication of this guideline in May 2013. An additional amendment was conducted in 2018 to reflect new literature released related to the treatment of patients with non-metastatic castration-resistant prostatecancer. This document will continue to be periodically updated to reflect the growing body of literature related to this disease. Panel Members Michael S
of malignanttumors. UICC International Union Against Cancer. 8th edn. 2017. 73. Cooperberg, M.R., et al. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol, 2005. 173: 1938. 74. Epstein, J.I., et al. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of ProstaticCarcinoma. Am J Surg Pathol, 2005. 29: 1228 (...) confers greater risk of biochemical progression. Urology, 2004. 64: 551. 253. Ploussard, G., et al. The prognostic significance of bladder neck invasion in prostatecancer: is microscopic involvement truly a T4 disease? BJU Int, 2010. 105: 776. 254. Hoedemaeker, R.F., et al. Stagingprostatecancer. Microsc Res Tech, 2000. 51: 423. 255. Stamey, T.A., et al. Prostatecancer is highly predictable: a prognostic equation based on all morphological variables in radical prostatectomy specimens. J Urol, 2000
Specific Antigen, serum protein associated with prostatecancer QoL Quality of life RD Risk difference RCT Randomized controlled trial RT Radiotherapy RTOG Radiation Therapy Oncology Group criteria, a scoring schema for radiation toxicity rV Volume of rectal tissue receiving a particular dose of radiation. E.g. rv70 is the volume of rectum receiving a dose of 70 Gy SBRT Stereotactic body radiation therapy TAU MUHC Technology Assessment Unit TNM Tumor Node Metastasis- Cancer classification VMAT (...) prostatecancer with low to intermediate risk. Hypofractionated radiotherapy delivers the conventional radiation dose of EBRT in fewer daily treatments. Hence, a larger daily dose of radiation (>2 Gy) is delivered in comparison with conventional EBRT. Hypofractionation or dose-escalation seeks to achieve more accurate targeting of the tumor while simultaneously increasing the dose of radiation. 2-4 However, as the rectum is adjacent to the prostate, it receives a substantial amount of radiation; hence
) or transperineal ultrasound guided biopsy (TPUSGB) using software fusion of previously acquired mpMRI images and ultrasound images. This method provides real-time ultrasound guidance but does not allow validation of the track of the biopsy needle through the identified mpMRI lesion as the MRI image is not live. MSAC noted that the application proposed these procedures would be used exclusively for the diagnosis of prostatecancer in patients who are likely to be at intermediate/high risk of the disease. MSAC (...) comparator (in Attachment) Type of economic evaluation Cost-utility Type of model 2 stage: 1) Decision tree for diagnostic accuracy of tests 2) Markov model for long-term effects of treatment and monitoring prostatecancer Sources of evidence ? Meta-analysis of diagnostic accuracy studies (Wegelin 2016) ? Clinical studies (Pokorny 2014) ? Registry data Starting age 65 years. Time horizon Lifetime (25 years) Outcomes QALYG, LYG, cost Methods used to generate results Cohort expected value analysis, Markov
Guideline for Optimization of Surgical and Pathological Quality Performance for Radical Prostatectomy in ProstateCancer Management | Cancer Care Ontario Google Tag Manager You are using an outdated browser. We suggest you update your browser for a better experience. for update. Browse Guidelines Browse Pathway Maps Sort by You are here / / Guideline for Optimization of Surgical and Pathological Quality Performance for Radical Prostatectomy in ProstateCancer Management Guidelines & Advice (...) Guideline for Optimization of Surgical and Pathological Quality Performance for Radical Prostatectomy in ProstateCancer Management english Version: 2 ID: 17-3 Oct 2017 Type of Content: Guidelines & Advice, Clinical Document Status: Current Authors: J. Chin, J. Srigley, L.A. Mayhew, R.B. Rumble, C. Crossley, A. Hunter, N. Fleshner, B. Bora, R. McLeod, S. McNair, B. Langer, A. Evans, ProstateCancer Surgery and Pathology Expert Panel Guideline Objective The objective of this document is to provide
of the prostate reproduce more rapidly than in a normal prostate, causing a tumour to develop. When the tumour is confined to the prostate gland it is considered to be localised. However, the cancer can metastasise to other parts of the body, particularly the bones and lymph nodes. 9 One of the symptoms of localised prostatecancer is difficulty passing urine, although the condition is often diagnosed at an asymptomatic stage, particularly when serum PSA levels are monitored. 10 Number of patients According (...) cryotherapy, irreversible electroporation, MRI-guided laser ablation and radiofrequency ablation, may address this clinical need, as there is some evidence that they have less toxicity than conventional therapies. However, the efficacy of these therapies is unclear, as several studies have shown high rates of persistent malignancy in the prostate glands so treated. Given that ablative techniques are offered as curative therapies for early prostatecancer and they are competing with well-established
in using these tracers (G Gillen and J Owens, NHS Greater Glasgow and Clyde. Personal communication, 6 Sept 2016). Evidence on 11 C- acetate was excluded from this evidence note on the advice of Scottish PET-CT experts. Staging of prostatecancer typically involves the use of routine imaging techniques such as magnetic resonance imaging (MRI) and CT for localised disease and lymph node involvement, and isotope bone scan for the assessment of bone metastases. Non-FDG PET-CT is also used in staging (...) of prostatecancer and is reported to have greater diagnostic value in staging of suspected relapsed prostatecancer (restaging) compared with staging in primary disease 6 . This evidence note compares the clinical effectiveness and cost effectiveness of choline tracers and novel non-FDG tracers, specifically anti- 18 F-FACBC and 68 Ga-PSMA, in restaging patients with suspected recurrent prostatecancer who have received treatment with curative intent. Health technology description PET-CT is a non
PSA) and the Phoenix definition (an increase of 2 ng/mL or more above the nadir PSA). The management of PCa depends on the TNM stage of the disease as well as both biochemical (e.g., PSA) and pathological information (e.g., Gleason score), which have prognostic value. The optimum treatment for a patient with PCa requires an assessment of the risk of both metastatic spread and local recurrence . [A0025] – How is prostatecancer currently managed according to published guidelines and in practice (...) the disease, while preserving continence and, if possible, potency  (B0001). Radiation therapy (RT) is another definitive treatment strategy in which a therapeutic dose of radi- ation is delivered to the tumour (either as external beam, brachytherapy, or a combination of both) while minimising the radiation to normal tissue. External beam RT (EBRT) utilises an external source of radiation to treat the prostate gland and a margin of adjacent normal tissue. Brachy- therapy directly implants a radioactive
. The CAP trial was a cluster-randomized trial of a single invitation to PSA-based screening in the United Kingdom among 415,357 men. Overall, 34% of invited men received a valid PSA screening test. After a median follow-up of 10 years, there was no significant difference in prostatecancer mortality between the invited group and the control group (absolute risk, 0.30 per 1000 person-years vs 0.31 per 1000 person-years, respectively). Based on clinical stage, tumor grade, and PSA level, prostatecancer (...) that current evidence suggests that treatment of early-stage, screen-detected prostatecancer with radical prostatectomy or radiation therapy likely reduces risk of clinical progression and metastatic disease and may reduce prostatecancer mortality. More details about the effectiveness and adverse effects of active treatment are provided in the Discussion section. Active surveillance is a treatment approach that seeks to limit the harms of treatment by allowing men with apparent low-risk prostatecancer
Prostatecancer - major changes in the American Joint Committee on Cancer eighth edition cancerstaging manual. Answer questions and earn CME/CNE The eighth edition of the American Joint Committee on Cancer (AJCC) tumor-node-metastasis (TNM) Staging Manual has been updated and improved to ensure the highest degree of clinical relevance and to improve its utility for patient evaluation and clinical research. Major changes include: 1) pathologically organ-confined disease is now considered pT2 (...) and is no longer subclassified by extent of involvement or laterality, 2) tumor grading now includes both the Gleason score (as in the seventh edition criteria) and the grade group (introduced in the eighth edition criteria), 3) prognostic stage group III includes select, organ-confined disease based on prostate-specific antigen and Gleason/grade group status, and 4) 2 statistical prediction models are included in the staging manual. The AJCC will continue to critically analyze emerging prostatecancer
in non-malignant tissue and decreased during cancer progression. High expression of Caveolin-1 in tumor stroma was associated with significantly longer cancer specific survival in prostatecancer patients. This association remained significant when Gleason score and local tumorstage were combined with Caveolin-1 in a Cox regression model. High stromal Caveolin-1 immunoreactivity in prostatetumors is associated with a favourable prognosis in prostatecancer patients managed by watchful waiting (...) High Caveolin-1 Expression in Tumor Stroma Is Associated with a Favourable Outcome in ProstateCancer Patients Managed by Watchful Waiting. In the present study we have investigated whether Caveolin-1 expression in non-malignant and malignantprostate tissue is a potential prognostic marker for outcome in prostatecancer patients managed by watchful waiting. Caveolin-1 was measured in prostate tissues obtained through transurethral resection of the prostate from 395 patients diagnosed
[Role of PET/CT with choline analogue radiotracers in the diagnosis and staging of prostatecancer] Papel do PET/TAC con radiofármacos análogos da colina no diagnóstico e estadificación do cancro de próstata [Role of PET/CT with choline analogue radiotracers in the diagnosis and staging of prostatecancer] Papel do PET/TAC con radiofármacos análogos da colina no diagnóstico e estadificación do cancro de próstata [Role of PET/CT with choline analogue radiotracers in the diagnosis and staging (...) of prostatecancer] Atienza Merino G Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Atienza Merino G. Papel do PET/TAC con radiofármacos análogos da colina no diagnóstico e estadificación do cancro de próstata. [Role of PET/CT with choline analogue radiotracers in the diagnosis and staging of prostatecancer] Santiago de Compostela: Galician Agency
Disparities in stagingprostate magnetic resonance imaging utilization for nonmetastatic prostatecancer patients undergoing definitive radiation therapy There is growing evidence supporting incorporating multiparametric (mp) magnetic resonance imaging (MRI) scans into risk stratification, active surveillance, and treatment paradigms for prostatecancer. The purpose of our study was to determine whether demographic disparities exist in staging MRI utilization for prostatecancer patients.An (...) across all risk groups and black or nonprivate insurance patients in the low risk group were less likely to undergo stagingprostate MRI scans. Further research should investigate these differences to ensure equitable utilization across all demographic groups considering the burden of prostatecancer disparities.